Effect of piracetam on polyphosphoinositide metabolism, cytosolic calcium release, and oxidative burst in human polymorphonuclear cells: Interaction with fMLP-induced stimulation

Biochemical Pharmacology

Volumn 57, Issue 2, 1999, Pages 163-170

  Tissot, Michèle ^a   Sarfati, Gilles ^b   Roch Arveiller, Monique ^a   Giroud, Jean Paul ^a  

^a CNRS   (France)

^b Hôpital Cochin ^*  (France)

Author keywords

fMLP; Human polymorphonuclears; Piracetam; Priming; Transduction

Indexed keywords

CYCLIC AMP; FORMYLMETHIONYLLEUCYLPHENYLALANINE; INOSITOL 1,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITIDE; PIRACETAM;

ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; HUMAN; HUMAN CELL; MEMBRANE BINDING; NEUTROPHIL; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; RECEPTOR AFFINITY; RESPIRATORY BURST;

CALCIUM; CHEMILUMINESCENT MEASUREMENTS; CYCLIC AMP; CYTOSOL; HUMANS; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; PHOSPHATIDYLINOSITOL PHOSPHATES; PIRACETAM; RESPIRATORY BURST; STIMULATION, CHEMICAL;

EID: 0032923650     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00295-0     Document Type: Article

References (32)

1. 32P into the phospholipids of neurons and glial cells isolated from rabbit cerebral cortex. Pharmakopsychiat. 12:1979;251-256.
2. Stoll L., Schubert T., Müller W.E. Age-related deficits of central muscarinic cholinergic receptor function in the mouse Partial restoration by chronic piracetam treatment . Neurobiol Aging. 13:1991;39-44.
3. Burnotte R.E., Gobert J.G., Temmerman J.J. Piracetam (2-pyrrolidone acetamide) induced modification of the brain polyribosome pattern in ageing rats. Biochem Pharmacol. 22:1973;811-814.
4. Vernon M.W., Sorkin E.M. Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drug Aging. 1:1991;17-35.
5. Boeckx W and Lismont D, The use of piracetam in the treatment of deep dermal burns. In: Abstracts of the XXIVth Congress Eur. Soc. Surg. Res. Brussels, 1989 (Eds. de Hemptinne B, Karran S and Lambotte L), p. 78. S. Karger Medical and Scientific Publishers, 1989.
6. Germonpre P., Reper P., Vanderkelen A. Hyperbaric oxygen therapy and piracetam decrease the early extension of deep partial-thickness burns. Burns. 22:1996;468-473.
7. Moriau M., Crasborn L., Lavenne-Pardonge E., von Frenckell R., Col-Debeys C. Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects. Arzneimittelforschung. 43:1993;110-118.
8. 31P nuclear magnetic resonance and conformational analysis. Biochem Pharmacol. 50:1995;1129-1134.
9. Muller W.E., Koch S., Scheuer K., Rostock A., Bartsch R. Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem Pharmacol. 53:1997;135-140.
10. Berridge M.J. Inositol trisphosphate and diacylglycerol as second messengers. Biochem J. 220:1984;345-360.
11. Dillon S.B., Murray J.J., Verghese M.W., Snyderman R. Regulation of inositol phosphate metabolism in chemoattractant-stimulated human polymorphonuclear leukocytes. J Biol Chem. 262:1987;11546-11552.
12. Cronstein B.N., Haines K.A. Stimulus-response uncoupling in the neutrophil. Biochem J. 281:1992;631-635.
13. Snyderman R., Uhing R.J. Chemoattractant stimulus-response coupling. Gallin J.I., Golstein I.M., Snyderman R. Inflammation, Basic Principles and Clinical Correlates. 1992;421-439 Raven Press, New York.
14. Koo C., Lefkowitz R.J., Snyderman R. The oligopeptide chemotactic factor receptor on human polymorphonuclear leukocyte membranes exits in two affinity states. Biochem Biophys Res Commun. 106:1982;442-449.
15. Snyderman R., Pike M.C. Chemoattractant receptors on phagocytic cells. Annu Rev Immunol. 2:1984;257-281.
16. Jesaitis AJ, Bokoch GM and Allen RA, Regulation of signal transduction in human neutrophils by cytoskeleton-mediated reorganization of the plasma membrane chemoattractant receptors. In: Signal Transduction in Cytoplasmic Organization and Cell Motility (Eds. Condeclis J, Lazarides E and Sakir P), pp. 325-337, Alan R. Liss, New York, 1988.
17. De Nardin E., Radel S.J., Genco R.J. Isolation and partial characterization of the formyl peptide receptor components on human neutrophils. Biochem Biophys Res Commun. 174:1991;84-89.
18. Zenou S.M., Raichvarg D., Agneray J. Unmodified phagocytosis after periodate treatment of human granulocytes separated by a two step method. Biomed Pharmacother. 35:1981;166-169.
19. Tissot M., Mathieu J., Mirossay L., Thuret A., Giroud J.P. Polyphosphoinositide metabolism in polymorphonuclear cells from healthy and thermally injured rats Effect of the immunomodulator RU 41740 . J Leukocyte Biol. 50:1991;607-614.
20. 2+-mobilizing hormones. Biochem J. 212:1983;733-747.
21. Downes C.P., Michell R.H. The polyphosphoinositide phosphodiesterase of erythrocyte membranes. Biochem J. 198:1981;133-140.
22. Berridge M.J., Dawson R.M.C., Downes C.P., Heslop J.P., Irvine R.F. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem J. 212:1983;473-482.
23. Périanin A., Snyderman R. Mastoparan, a wasp venom peptide, identifies two discrete mechanisms for elevating cytosolic calcium and inositol trisphosphates in human polynuclear leukocytes. J Immunol. 146:1989;1669-1673.
24. 2+ indicators with greatly improved fluorescence properties. J Biol Chem. 260:1985;3440-3450.
25. Allen R.C., Stjernholm R.L., Steele R.H. Evidence for the generation of an electronic state(s) in human polymorphonuclear leukocytes and its participation in bactericidal activity. Biochem Biophys Res Commun. 47:1972;679-684.
26. Johnston R.B., Keel B.B., Misra H.P., Lehmeyer J.E., Webb L.S., Baehner R.L., Rajacopalan K.V. The role of superoxide anion generation in phagocytic bacterial activity. J Clin Invest. 55:1975;1357-1372.
27. Bellavite P., Chirumbolo S., Lippi G., Guzzo P., Santonastaso C. Homologous priming in chemotactic peptide-stimulated neutrophils. Cell Biochem Funct. 11:1993;93-100.
28. Gouliaev A.H., Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev. 19:1994;180-222.
29. Verbnyi Y.I., Derzhiruk L.P., Mogilevskii A.Y. Piracetam-induced changes in the functional activity of neurons as a possible mechanism for the effects of nootropic agents. Neurosci Behav Physiol. 26:1996;507-515.
30. Solntseva E.I., Bukanova J.V., Ostrovskaya R.U., Gudasheva T.A., Voronina T.A., Skrebitsky V.G. The effects of piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channels. Gen Pharmacol. 29:1997;85-89.
31. Thelen M., Dewald B., Baggiolini M. Neutrophil signal transduction and activation of the respiratory burst. Physiol Rev. 73:1993;797-821.
32. Snyderman R., Smith C.D., Verghese M.W. Model for leukocyte regulation by chemoattractant receptors Roles of a guanine nucleotide regulatory protein and polyphosphoinositide metabolism . J Leukocyte Biol. 40:1986;785-800.